"Low and Slow" vs "One and Done"? Unlocking the Potential of Gene Therapy

Video

Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences, joins CGTL to discuss ImmTOR, an immune tolerance platform that could ultimately enable gene therapy redosing in certain cases.

"This study has quite broad implications. It's the first time anyone has shown in a human healthy volunteer study that we can inhibit the formation of antibodies, which, down the line, might enable redosing." — Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences

The prime concern in gene therapy development, of course, is safety, and one of the limitations of adeno-associated virus (AAV) gene therapy is that it is traditionally thought of as "one and done," in that one dose is highly immunogenic.

But what if a "low and slow" approach was possible and enabled potentially safe and efficacious redosing?

That is the idea behind Selecta Biosciences' ImmTORTM platform, which seeks to mitigate unwanted immune responses that can interfere with the activity of biologic therapies.

Joining CGTL is Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences, to discuss ImmTORTM, as well as the company's clinical programs, including SEL-302 for methylmalonic acidemia (MMA).

Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.